ArticleCarcinogenesis2013

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Haiying Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.